| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
These potential therapeutic opportunities utilizing RNAi in vivo are just now being recognized injected from vein, however, the effects of RNAi in vivo injected from renal artery is not well known. It is useful clinically to deliver the vector locally through trans-aortic cathether to reduce adverse effect of siRNA theraphy.Therefore, we chose inhibition of p53 expression following ischemia-reperfusion injury(IR) injected from renal artery as a means to test the efficacy of siRNA in vivo in reducing tubular cell injury and improving renal function.
|
